Back to Search
Start Over
Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
- Source :
-
Clinical and vaccine immunology : CVI [Clin Vaccine Immunol] 2014 Jun; Vol. 21 (6), pp. 901-3. Date of Electronic Publication: 2014 Apr 16. - Publication Year :
- 2014
-
Abstract
- Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso). The low neutralizing antibody titers reported in both adults and children (median titers, 139.1 and 35.0, respectively) are encouraging for the potential use of ChAd63 as a malarial vaccine vector.<br /> (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Subjects :
- Adenoviruses, Simian classification
Adolescent
Adult
Animals
Antibodies, Neutralizing immunology
Antibodies, Viral immunology
Burkina Faso
Child
Child, Preschool
Cohort Studies
Humans
Infant
Malaria, Falciparum prevention & control
Middle Aged
Pan troglodytes
Young Adult
Adenoviruses, Simian immunology
Antibodies, Neutralizing blood
Antibodies, Viral blood
Malaria Vaccines immunology
Malaria, Falciparum immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1556-679X
- Volume :
- 21
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Clinical and vaccine immunology : CVI
- Publication Type :
- Academic Journal
- Accession number :
- 24739980
- Full Text :
- https://doi.org/10.1128/CVI.00723-13